Objective To observe the curative effect of levetiracetam on intractable epilepsy and its influence on immune function. Methods From Feb. 2013 to Feb. 2016, 100 patients with intractable epilepsy in our hospital were randomly divided into control group (n=50) and observation group (n=50). The control group was given carbamazepine, and the observation group was given levetiracetam. The curative effects, immune function and adverse reactions in the two groups were compared. Results The total effective rate in the observation group was 88% which was significantly higher than that in the control group 70% (P<0.05), after treatment, the levels of CD4+, IgA and IgG in the two groups were significantly increased (P<0.05), but the CD8+ levels in the two groups were significantly decreased (P<0.05), the increase of CD4+, IgA, IgG and decrease of CD8+ in the observation group were all significantly higher than those in the control group (P<0.05), the incidence rate of adverse reactions in the observation group was 10% which was lower than that in the control group 12%, but their difference was not statistically significant (P>0.05). Conclusion Levetiracetam which is effective in the treatment of intractable epilepsy, can improve the immune function of patients.